Cargando…

伴有SMARCA4缺失的非小细胞肺癌9例临床病理分析

BACKGROUND AND OBJECTIVE: SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is a rare primary lung malignancy. These diseases are not listed separately in the 2021 World Health Organization (WHO) classification of lung neoplasms, but they have special morphological, immunophenotypic and...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411953/
https://www.ncbi.nlm.nih.gov/pubmed/36002194
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.27
_version_ 1784775382170337280
collection PubMed
description BACKGROUND AND OBJECTIVE: SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is a rare primary lung malignancy. These diseases are not listed separately in the 2021 World Health Organization (WHO) classification of lung neoplasms, but they have special morphological, immunophenotypic and molecular genetic characteristics. This study aims to improve understanding of SMARCA4-dNSCLC by discussing the clinicopathological features, diagonosis and differential diagnosis of the disease. METHODS: The clinical and imaging data of 9 cases of SMARCA4-dNSCLC diagnosed in Shanghai Changhai Hospital from January 2020 to March 2022 were collected. The clinicopathological features were analyzed by histological and immunohistochemical staining, and the literature was reviewed. RESULTS: The median age of 9 patients was 65 years old. Six men were smokers. The average maximum diameter of tumor was 3.3 cm. Six cases had been metastasized. The imaging showed that it was an infiltrating mass with unclear boundary and 3 cases invaded the pleura. Nine cases were diagnosed as SMARCA4-dNSCLC, which mainly showed three pathological forms including classic lung adenocarcinoma, mucinous adenocarcinoma and poorly differentiated carcinoma. Poorly differentiated tumor cells are epithelioid, syncytial or rhabdomyoid, the cytoplasm was rich, the cytoplasm could be completely transparent to eosinophilic, eosinophilic globules or small abscesses could be seen, showing solid flakes, with more inflammatory cells and flake necrosis in the stroma. Immunohistochemistry showed that SMARCA4 was negative in all cases and eight cases demonstrated cytokeratin 5.2 (CAM5.2) and cytokeratin 7 (CK7) was diffusely strongly positive, p40 was negative, thyroid transcription factor-1 (TTF-1) was negative in 6 cases, partially positive in 2 cases and diffusely positive in 1 case. CONCLUSION: SMARCA4-dNSCLC is a rare subtype of lung cancer with complex and diverse pathological morphology. The characteristic of immunohistochemical phenotype can assist in the diagnosis.
format Online
Article
Text
id pubmed-9411953
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-94119532022-09-12 伴有SMARCA4缺失的非小细胞肺癌9例临床病理分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is a rare primary lung malignancy. These diseases are not listed separately in the 2021 World Health Organization (WHO) classification of lung neoplasms, but they have special morphological, immunophenotypic and molecular genetic characteristics. This study aims to improve understanding of SMARCA4-dNSCLC by discussing the clinicopathological features, diagonosis and differential diagnosis of the disease. METHODS: The clinical and imaging data of 9 cases of SMARCA4-dNSCLC diagnosed in Shanghai Changhai Hospital from January 2020 to March 2022 were collected. The clinicopathological features were analyzed by histological and immunohistochemical staining, and the literature was reviewed. RESULTS: The median age of 9 patients was 65 years old. Six men were smokers. The average maximum diameter of tumor was 3.3 cm. Six cases had been metastasized. The imaging showed that it was an infiltrating mass with unclear boundary and 3 cases invaded the pleura. Nine cases were diagnosed as SMARCA4-dNSCLC, which mainly showed three pathological forms including classic lung adenocarcinoma, mucinous adenocarcinoma and poorly differentiated carcinoma. Poorly differentiated tumor cells are epithelioid, syncytial or rhabdomyoid, the cytoplasm was rich, the cytoplasm could be completely transparent to eosinophilic, eosinophilic globules or small abscesses could be seen, showing solid flakes, with more inflammatory cells and flake necrosis in the stroma. Immunohistochemistry showed that SMARCA4 was negative in all cases and eight cases demonstrated cytokeratin 5.2 (CAM5.2) and cytokeratin 7 (CK7) was diffusely strongly positive, p40 was negative, thyroid transcription factor-1 (TTF-1) was negative in 6 cases, partially positive in 2 cases and diffusely positive in 1 case. CONCLUSION: SMARCA4-dNSCLC is a rare subtype of lung cancer with complex and diverse pathological morphology. The characteristic of immunohistochemical phenotype can assist in the diagnosis. 中国肺癌杂志编辑部 2022-08-20 /pmc/articles/PMC9411953/ /pubmed/36002194 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.27 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 临床研究
伴有SMARCA4缺失的非小细胞肺癌9例临床病理分析
title 伴有SMARCA4缺失的非小细胞肺癌9例临床病理分析
title_full 伴有SMARCA4缺失的非小细胞肺癌9例临床病理分析
title_fullStr 伴有SMARCA4缺失的非小细胞肺癌9例临床病理分析
title_full_unstemmed 伴有SMARCA4缺失的非小细胞肺癌9例临床病理分析
title_short 伴有SMARCA4缺失的非小细胞肺癌9例临床病理分析
title_sort 伴有smarca4缺失的非小细胞肺癌9例临床病理分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411953/
https://www.ncbi.nlm.nih.gov/pubmed/36002194
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.27
work_keys_str_mv AT bànyǒusmarca4quēshīdefēixiǎoxìbāofèiái9lìlínchuángbìnglǐfēnxī
AT bànyǒusmarca4quēshīdefēixiǎoxìbāofèiái9lìlínchuángbìnglǐfēnxī
AT bànyǒusmarca4quēshīdefēixiǎoxìbāofèiái9lìlínchuángbìnglǐfēnxī
AT bànyǒusmarca4quēshīdefēixiǎoxìbāofèiái9lìlínchuángbìnglǐfēnxī
AT bànyǒusmarca4quēshīdefēixiǎoxìbāofèiái9lìlínchuángbìnglǐfēnxī
AT bànyǒusmarca4quēshīdefēixiǎoxìbāofèiái9lìlínchuángbìnglǐfēnxī